Bilirakis Applauds Progress on Drug Prices, Public Health Bills
Washington, D.C. – Today, U.S. Rep. Gus Bilirakis (FL-12) applauded progress made on legislation he championed to lower the price of prescription medication, and reauthorize research programs for congenital heart disease and sickle cell disease.
During the markup, Bilirakis spoke on the importance of incentivizing generic drug production to tackle the issue of high drug prices. He worked closely on a provision in the FDA Reauthorization Act which would accelerate the generic drug approval process and encourage generic drug makers to enter markets where there is no competition.
“Too often, bad actors in the marketplace take advantage of monopolies, skyrocketing the price of lifesaving medication simply because there is little to no competition,” Bilirakis said.
The Congressman also discussed legislation he introduced, the Congenital Heart Futures Reauthorization Act, which continues research on the treatment and prevention of congenital heart disease (CHD). “For the sake of the estimated 40,000 babies who will be born in the next year with CHD, there’s more work to be done to better understand this diagnosis,” Bilirakis noted.
The bills were approved by the Energy and Commerce Subcommittee on Health, and will next be considered by the entire Energy and Commerce Committee before reaching the House floor.
Please click here for more information on the bills: the FDA Reauthorization Act (H.R. 2430), the Congenital Heart Futures Reauthorization Act (H.R. 1222), and the Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act (H.R. 2410).